FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307808596> ?p ?o ?g. }

• W4307808596 endingPage "4112" @default.
• W4307808596 startingPage "4096" @default.
• W4307808596 abstract "At present, there is no accurate biomarker for immune checkpoint inhibitors (ICIs). Since the efficacy of ICIs is associated with a variety of indicators, establishing a model to predict its efficacy is more clinically significant and in line with clinical needs.We collected and retrospectively analyzed the relationship between immunotherapy efficacy and clinicopathologic features in lung adenocarcinoma patients treated with ICIs. Progression-free survival (PFS) and overall survival (OS) were analyzed. Univariate and multivariate Cox proportional hazards regression analyses were conducted to identify prognostic factors associated with PFS. Besides, a clinical prediction model was established based on the results of the multivariate Cox regression analyses to predict PFS.A total of 201 lung adenocarcinoma patients treated with ICIs were assessed. Univariate analysis showed that male gender [hazard ratio (HR) =0.521, 95% confidence interval (CI): 0.356-0.761, P=0.001], smoking (HR =0.595, 95% CI: 0.420-0.843, P=0.003), epidermal growth factor receptor (EGFR) wild type (HR =2.766, 95% CI: 1.719-4.452, P<0.001), Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation (HR =0.449, 95% CI: 0.271-0.743, P=0.001), positive programmed death ligand 1 (PD-L1) expression (HR =0.527, 95% CI: 0.336-0.825, P=0.004), early tumor node metastasis (TNM) stage (HR =0.581, 95% CI: 0.344-0.983, P=0.039), no liver metastasis (HR =1.801, 95% CI: 1.046-3.102, P=0.031), ICIs combined with chemotherapy (HR =0.560, 95% CI: 0.384-0.815, P=0.002), having immune-related adverse effects (HR =0.354, 95% CI: 0.228-0.511, P<0.001) and first-line immunotherapy (HR =0.596, 95% CI: 0.420-0.845, P=0.003) were significantly associated with better PFS in patients with lung adenocarcinoma receiving immunotherapy. Multivariate analysis showed that smoking status, KRAS mutation, PD-L1 expression, line of immunotherapy and immune-related adverse effects were independent prognostic factors affecting PFS. A clinical prediction model was established to predict the PFS of lung adenocarcinoma patients treated with ICIs. The model showed good predictive ability via C-index, calibration curve and receiver operating characteristic (ROC) curve validation.The clinical prediction model developed in this study can be used to some extent to predict PFS after immunotherapy in lung adenocarcinoma patients. However, the model still needs to be validated in studies with large sample size." @default.
• W4307808596 created "2022-11-06" @default.
• W4307808596 creator A5014923511 @default.
• W4307808596 creator A5024958140 @default.
• W4307808596 creator A5026015484 @default.
• W4307808596 creator A5048399715 @default.
• W4307808596 creator A5055526321 @default.
• W4307808596 creator A5064414647 @default.
• W4307808596 date "2022-10-01" @default.
• W4307808596 modified "2023-09-28" @default.
• W4307808596 title "Clinical predictors of treatment efficacy and a prognostic nomogram in patients with lung adenocarcinoma receiving immune checkpoint inhibitors: a retrospective study" @default.
• W4307808596 cites W2104347254 @default.
• W4307808596 cites W2156353875 @default.
• W4307808596 cites W2527905628 @default.
• W4307808596 cites W2572174216 @default.
• W4307808596 cites W2581283430 @default.
• W4307808596 cites W2761155767 @default.
• W4307808596 cites W2784283849 @default.
• W4307808596 cites W2792273180 @default.
• W4307808596 cites W2796582438 @default.
• W4307808596 cites W2804812017 @default.
• W4307808596 cites W2892640821 @default.
• W4307808596 cites W2900082702 @default.
• W4307808596 cites W2914427235 @default.
• W4307808596 cites W2925446385 @default.
• W4307808596 cites W2962618676 @default.
• W4307808596 cites W2964471257 @default.
• W4307808596 cites W2968156253 @default.
• W4307808596 cites W2981114563 @default.
• W4307808596 cites W2985170860 @default.
• W4307808596 cites W2998945317 @default.
• W4307808596 cites W3003299955 @default.
• W4307808596 cites W3005292744 @default.
• W4307808596 cites W3012466751 @default.
• W4307808596 cites W3045354166 @default.
• W4307808596 cites W3080948982 @default.
• W4307808596 cites W3084896449 @default.
• W4307808596 cites W3087229737 @default.
• W4307808596 cites W3109273351 @default.
• W4307808596 cites W3114743310 @default.
• W4307808596 cites W3128646645 @default.
• W4307808596 cites W3157248895 @default.
• W4307808596 cites W3158078460 @default.
• W4307808596 cites W3162404444 @default.
• W4307808596 cites W3170676376 @default.
• W4307808596 cites W3192721002 @default.
• W4307808596 cites W3192924832 @default.
• W4307808596 cites W3197015296 @default.
• W4307808596 cites W3199548858 @default.
• W4307808596 cites W3207617005 @default.
• W4307808596 doi "https://doi.org/10.21037/jtd-22-1270" @default.
• W4307808596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36389292" @default.
• W4307808596 hasPublicationYear "2022" @default.
• W4307808596 type Work @default.
• W4307808596 citedByCount "2" @default.
• W4307808596 countsByYear W43078085962023 @default.
• W4307808596 crossrefType "journal-article" @default.
• W4307808596 hasAuthorship W4307808596A5014923511 @default.
• W4307808596 hasAuthorship W4307808596A5024958140 @default.
• W4307808596 hasAuthorship W4307808596A5026015484 @default.
• W4307808596 hasAuthorship W4307808596A5048399715 @default.
• W4307808596 hasAuthorship W4307808596A5055526321 @default.
• W4307808596 hasAuthorship W4307808596A5064414647 @default.
• W4307808596 hasBestOaLocation W43078085961 @default.
• W4307808596 hasConcept C121608353 @default.
• W4307808596 hasConcept C126322002 @default.
• W4307808596 hasConcept C143998085 @default.
• W4307808596 hasConcept C144301174 @default.
• W4307808596 hasConcept C207103383 @default.
• W4307808596 hasConcept C2776256026 @default.
• W4307808596 hasConcept C2781182431 @default.
• W4307808596 hasConcept C2781187634 @default.
• W4307808596 hasConcept C34626388 @default.
• W4307808596 hasConcept C38180746 @default.
• W4307808596 hasConcept C44249647 @default.
• W4307808596 hasConcept C50382708 @default.
• W4307808596 hasConcept C526805850 @default.
• W4307808596 hasConcept C71924100 @default.
• W4307808596 hasConceptScore W4307808596C121608353 @default.
• W4307808596 hasConceptScore W4307808596C126322002 @default.
• W4307808596 hasConceptScore W4307808596C143998085 @default.
• W4307808596 hasConceptScore W4307808596C144301174 @default.
• W4307808596 hasConceptScore W4307808596C207103383 @default.
• W4307808596 hasConceptScore W4307808596C2776256026 @default.
• W4307808596 hasConceptScore W4307808596C2781182431 @default.
• W4307808596 hasConceptScore W4307808596C2781187634 @default.
• W4307808596 hasConceptScore W4307808596C34626388 @default.
• W4307808596 hasConceptScore W4307808596C38180746 @default.
• W4307808596 hasConceptScore W4307808596C44249647 @default.
• W4307808596 hasConceptScore W4307808596C50382708 @default.
• W4307808596 hasConceptScore W4307808596C526805850 @default.
• W4307808596 hasConceptScore W4307808596C71924100 @default.
• W4307808596 hasIssue "10" @default.
• W4307808596 hasLocation W43078085961 @default.
• W4307808596 hasLocation W43078085962 @default.
• W4307808596 hasLocation W43078085963 @default.
• W4307808596 hasOpenAccess W4307808596 @default.
• W4307808596 hasPrimaryLocation W43078085961 @default.

• next